Authors (including presenting author) :
Lo YM, Chou PK, Mak KY, Mak WL, Yeung WY, Leung YS, Wan YT, Hung SY, Lai SY, Leung KF, Leung WCW, Tsui PN, Leung WMW, Li HLF, Wong MSM, Wong MYM
Affiliation :
Department of Family Medicine and Primary Healthcare, Hong Kong East Cluster
Keyword 1: :
Empowering Diabetes Patients in Self-Management
Keyword 2: :
Continuous Glucose Monitoring Systems (CGMS)
Keyword 3: :
Family Medicine Clinic
Introduction :
The integration of Continuous Glucose Monitoring Systems (CGMS) in diabetes management has revolutionized the approach to self-care, particularly in primary healthcare settings. CGMS empower diabetic patients to enhance self-management by facilitating lifestyle modifications, glucose monitoring, and therapy adjustments. This study aims to evaluate the implementation and impact of CGMS on empowering diabetes patients in self-management. Launched in April 2024 at the Wan Chai Violet Peel Family Medicine Clinic (FMC), the program expanded by 2025 to encompass five additional FMCs, enhancing support for diabetes management especially for patients with complex treatment regimens.
Objectives :
- To acquire practical experience in the use of CGMS - To ensure patient safety amid increasingly intricate therapeutic approaches - To empower patients to engage actively in self-monitoring and care management
Methodology :
Inclusion and exclusion criteria were established for patient selection. Workflow protocols were developed for the roles of doctors, nurses and patient care assistants to optimize patient education and management processes. The project commenced at FMCs in April 2024, involving patient referrals for CGMS installation, followed by a 14-day monitoring period. Nurses educated patients about CGMS use and assisted in reviewing CGMS reports. Doctors played a pivotal role in analyzing these reports for effective management of patient therapy.
Result & Outcome :
Between April and December 2025, 39 patients completed CGMS program. The monitoring results indicated that 64.1% of participants achieved the target time in range (TIR) of over 70%, and 69.2% maintained glucose variability (GV) within acceptable limits. Additionally, 71.8% of patients had their post-CGM HbA1c checked. Among them, the percentage of patients with suboptimal glycemic control (HbA1c of 7.5% or higher) dropped from 93% to 64%. Conclusively, 78.5% showed improvement in HbA1c, with 63.6% of patients decreasing HbA1c by 0.1%-0.9%, 22.7% decreasing HbA1c by 1.0%-1.9%, and 13.6% decreasing HbA1c by 2.0%-4.6%. Furthermore, a patient experience survey with 29 respondents revealed positive feedback, highlighting the benefits of real-time data and reminders for hypo/hyperglycemia. Ultimately, 79.3% of participants expressed satisfaction with the CGMS services provided. Moving forward, ongoing evaluation will be essential for assessing long-term outcomes and refining the CGMS program.
